Geode Capital Management
SKYE icon

Geode Capital Management’s Skye Bioscience SKYE Stock Holding History

Geode Capital Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$170K Buy
277,256
+67,105
+32% +$54.7K ﹤0.01% 3970
2025
Q4 		$158K Buy
210,151
+1,553
+0.7% +$2.27K ﹤0.01% 3987
2025
Q3 		$820K Buy
208,598
+6,677
+3% +$25.2K ﹤0.01% 3451
2025
Q2 		$844K Sell
201,921
-238,873
-54% -$494K ﹤0.01% 3382
2025
Q1 		$701K Buy
440,794
+35,100
+9% +$95.8K ﹤0.01% 3427
2024
Q4 		$1.15M Buy
405,694
+19,901
+5% +$83.2K ﹤0.01% 3324
2024
Q3 		$1.51M Buy
385,793
+15,614
+4% +$87.6K ﹤0.01% 3210
2024
Q2 		$2.97M Buy
+370,179
New +$4.39M ﹤0.01% 2987

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management's SKYE Position: Q1 2026 in Review

Geode Capital Management increased its Skye Bioscience (SKYE) stake by 32% in Q1 2026, buying an estimated $54.7K and bringing the position to 277,256 shares worth $170K. The position accounts for ﹤0.01% of the portfolio, ranked #3970.

Geode Capital Management first reported a position in SKYE in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.97M in Q2 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Geode Capital Management held 277,256 shares of Skye Bioscience worth $170K as of Q1 2026.
  • Geode Capital Management bought 67,105 Skye Bioscience shares in Q1 2026, an estimated $54.7K.
  • Skye Bioscience made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3970 holding.
  • Geode Capital Management first reported a position in Skye Bioscience in Q2 2024 and has held it in 8 quarters since.
  • Geode Capital Management's Skye Bioscience position peaked at $2.97M in Q2 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.